CENTOGENE Data on Novel Genetic Risk Factor for Parkinson’s Disease in The Lancet Neurology
September 25, 2024 08:00 ET
|
Centogene NV
Rostock International Parkinson's Disease (ROPAD) Study demonstrates a significant link between the RAB32 gene variant and Parkinson's disease, further supporting recent findingsData from over...
Avadel Pharmaceuticals Announces Publication of Data Highlighting Efficacy of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension in Improving Narcolepsy Symptoms Regardless of Concomitant Use of an Alerting Agent
September 25, 2024 08:00 ET
|
Avadel Pharmaceuticals plc
– Post-hoc analysis from pivotal Phase 3 REST-ON trial confirmed the efficacy of LUMRYZ in study participants who were and were not using a stable dose of an alerting agent – – Baseline data...
Aprea Therapeutics to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
September 25, 2024 08:00 ET
|
Aprea Therapeutics
DOYLESTOWN, Pa., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology...
Tactile Medical Announces Positive Clinical Trial Results in Lymphedema Patients Using Advanced Pneumatic Compression Device Therapy
September 25, 2024 08:00 ET
|
Tactile Systems Technology, Inc.
MINNEAPOLIS, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with...
TTM Technologies, Inc. wins Cisco 2024 Supply Chain Security Champion Award
September 25, 2024 08:00 ET
|
TTM Technologies, Inc.
SANTA ANA, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- TTM Technologies, Inc. (NASDAQ: TTMI) (“TTM”), a leading global manufacturer of technology solutions including mission systems, radio frequency...
Synchronoss Introduces Enhanced Version of Flagship Personal Cloud Platform for Service Providers
September 25, 2024 08:00 ET
|
Synchronoss Technologies, Inc.
New Synchronoss Personal Cloud Adds Features Such as Memories and Built-In AI Functionality to Make it Even Easier for Subscribers to Optimize Content
NV5 Announces 4-for-1 Stock Split; Enhances Accessibility of Stock Ownership for Employees and Investors
September 25, 2024 08:00 ET
|
NV5 Global, Inc.
HOLLYWOOD, Fla., Sept. 25, 2024 (GLOBE NEWSWIRE) -- NV5 Global, Inc. (the “Company” or “NV5”) (Nasdaq: NVEE), a provider of technology, certification, and consulting solutions, announced that it...
Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium
September 25, 2024 08:00 ET
|
Erasca, Inc.
Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor Erasca is also evaluating naporafenib plus trametinib in the ongoing SEACRAFT-2 pivotal Phase 3 trial in NRAS-mutant...
Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis
September 25, 2024 08:00 ET
|
Palisade Bio, Inc.
– Completion of nonclinical safety and toxicity studies, Phase 1 clinical trial design and established Maximum Recommended Starting Dose – Completion of pre- Clinical Trial Application (CTA)...
Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension
September 25, 2024 08:00 ET
|
Mineralys Therapeutics, Inc.
– On track to announce topline data in Q1 2025 – – Virtual KOL event scheduled on October 30th to discuss the unmet need in hypertension, as well as a review of the ongoing pivotal clinical program...